1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 2: 
Clinical and demographic summary for training and test set groupsa
TrainingTest
Diagnosis (GBM/NGG/Other)24/4/18/6/1
Age (yr)62.5 (12.9)55.8 (14.5)
Overall survival (mo)39.9 (69.5)41.3 (44.9)
Radiation treatment (y/n)25/414/1
Chemotherapy (y/n)26/314/1
Tumor-treating fields (y/n)12/174/11
Other treatment (y/n)3/264/11
Time between last MR imaging and death (days)46.2 (39.2)95.5 (83.9)
  • Note:—Y/n indicates yes/no.
  • ↵a Quantitative values are presented as mean (SD).